Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliferation and enhances apoptosis in breast cancer cells

Cancer Biol Ther. 2006 Jul;5(7):842-7. doi: 10.4161/cbt.5.7.2840. Epub 2006 Jul 21.

Abstract

Breast cancer, the most common malignancy in women, has a known association with the steroid hormone estrogen. Estrogen receptor alpha (ERalpha) plays an important role in the clinical care of breast cancer patients, both as a prognostic factor and as a therapeutic target. Here, we show that a small interfering RNA (siRNA) against ERalpha downregulates ERalpha expression in human MCF-7 and Bcap-37 breast cancer cells, causing a significant decrease in breast cancer cell proliferation. Tumor cells lacking ERalpha expression grew at a much slower rate than did control cells in vitro. Moreover, ERalpha knockdown in breast cancer cells resulted in decreased, even completely abrogated tumor growth in BALB/c nude mice, providing direct evidence for an essential role of ERalpha in breast cancer growth. Our results suggest siRNA-mediated gene silencing of ERalpha may impair tumorigenicity, and even suppress the tumor growth.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Breast Neoplasms / therapy*
  • Cell Line, Tumor
  • Cell Proliferation
  • Estrogen Receptor alpha / antagonists & inhibitors*
  • Estrogen Receptor alpha / genetics
  • Female
  • Genetic Therapy / methods*
  • Genetic Vectors / genetics
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • RNA Interference*
  • RNA, Small Interfering / genetics
  • Xenograft Model Antitumor Assays

Substances

  • Estrogen Receptor alpha
  • RNA, Small Interfering